Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rajkumar, S. V.
Right arrow Articles by Witzig, T. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rajkumar, S. V.
Right arrow Articles by Witzig, T. E.
Journal of Clinical Oncology, Vol 20, Issue 21 (November), 2002: 4319-4323
© 2002 American Society for Clinical Oncology

Combination Therapy With Thalidomide Plus Dexamethasone for Newly Diagnosed Myeloma

By S. Vincent Rajkumar, Suzanne Hayman, Morie A. Gertz, Angela Dispenzieri, Martha Q. Lacy, Philip R. Greipp, Susan Geyer, Nancy Iturria, Rafael Fonseca, John A. Lust, Robert A. Kyle, Thomas E. Witzig

From the Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN.

Address reprint requests to S. Vincent Rajkumar, MD, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905; email: rajks{at}mayo.edu

PURPOSE: Multiple myeloma is a malignancy of plasma cells and is characterized by increased marrow angiogenesis. Thalidomide, an agent with antiangiogenic properties, is effective in relapsed myeloma. We report the results of a study combining thalidomide and dexamethasone as initial therapy for myeloma.

PATIENTS AND METHODS: Fifty patients with newly diagnosed myeloma were studied. Thalidomide was given at a dose of 200 mg/d orally. Dexamethasone was given at a dose of 40 mg/d orally on days 1 to 4, 9 to 12, and 17 to 20 (odd cycles) and 40 mg/d on days 1 to 4 (even cycles), repeated monthly.

RESULTS: Of all 50 patients, a confirmed response was seen in 32 patients yielding a response rate of 64% (95% confidence interval, 49% to 77%). Thirty-one patients (62%) proceeded to stem-cell collection after four cycles of therapy including 26 who underwent stem-cell transplantation and five who chose stem-cell cryopreservation. Major grade 3 or 4 toxicities were observed in 16 patients (32%), and the most frequent were deep vein thrombosis (six patients), constipation (four patients), rash (three patients), and dyspnea (two patients). Three deaths occurred during active therapy because of a pancreatitis, pulmonary embolism, and infection.

CONCLUSION: We conclude that the combination of thalidomide plus dexamethasone is a feasible and active regimen in the treatment of multiple myeloma. It merits further study as an oral alternative to infusional chemotherapy with vincristine, doxorubicin, and dexamethasone and other intravenous regimens currently used as pretransplantation induction therapy for myeloma.




This article has been cited by other articles:


Home page
 JCOHome page
S. V. Rajkumar, L. Rosinol, M. Hussein, J. Catalano, W. Jedrzejczak, L. Lucy, M. Olesnyckyj, Z. Yu, R. Knight, J. B. Zeldis, et al.
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma
J. Clin. Oncol., May 1, 2008; 26(13): 2171 - 2177.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
E. N. Brown and J. D. Herrington
Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment
Journal of Pharmacy Practice, April 1, 2008; 21(2): 126 - 137.
[Abstract] [PDF]

Home page
 BloodHome page
A. Abdelkefi, S. Ladeb, L. Torjman, T. B. Othman, A. Lakhal, N. B. Romdhane, H. E. Omri, M. Elloumi, H. Belaaj, R. Jeddi, et al.
Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial
Blood, February 15, 2008; 111(4): 1805 - 1810.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
B. Vahid and P. E. Marik
Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors
Chest, February 1, 2008; 133(2): 528 - 538.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Niesvizky, D. S. Jayabalan, P. J. Christos, J. R. Furst, T. Naib, S. Ely, J. Jalbrzikowski, R. N. Pearse, F. Zafar, K. Pekle, et al.
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
Blood, February 1, 2008; 111(3): 1101 - 1109.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Bensinger
Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Drugs
J. Clin. Oncol., January 20, 2008; 26(3): 480 - 492.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
H. M. Lokhorst, I. Schmidt-Wolf, P. Sonneveld, B. van der Holt, H. Martin, R. Barge, U. Bertsch, J. Schlenzka, G. M.J. Bos, S. Croockewit, et al.
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
Haematologica, January 1, 2008; 93(1): 124 - 127.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. M. Weber, C. Chen, R. Niesvizky, M. Wang, A. Belch, E. A. Stadtmauer, D. Siegel, I. Borrello, S. V. Rajkumar, A. A. Chanan-Khan, et al.
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
N. Engl. J. Med., November 22, 2007; 357(21): 2133 - 2142.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
K. V. Rao
Lenalidomide in the treatment of multiple myeloma
Am. J. Health Syst. Pharm., September 1, 2007; 64(17): 1799 - 1807.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. G. Richardson, C. Mitsiades, R. Schlossman, N. Munshi, and K. Anderson
New Drugs for Myeloma
Oncologist, June 1, 2007; 12(6): 664 - 689.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Fonseca and A. K. Stewart
Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach
Mol. Cancer Ther., March 1, 2007; 6(3): 802 - 810.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Suvannasankha, C. Fausel, B. E. Juliar, C. T. Yiannoutsos, W. B. Fisher, R. H. Ansari, L. L. Wood, G. G. Smith, L. D. Cripe, and R. Abonour
Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial, HEM01-21
Oncologist, January 1, 2007; 12(1): 99 - 106.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. G. Richardson, E. Blood, C. S. Mitsiades, S. Jagannath, S. R. Zeldenrust, M. Alsina, R. L. Schlossman, S. V. Rajkumar, K. R. Desikan, T. Hideshima, et al.
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
Blood, November 15, 2006; 108(10): 3458 - 3464.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Attal, J.-L. Harousseau, S. Leyvraz, C. Doyen, C. Hulin, L. Benboubker, I. Y. Agha, J.-H. Bourhis, L. Garderet, B. Pegourie, et al.
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma
Blood, November 15, 2006; 108(10): 3289 - 3294.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
H. P. Sviggum, M. D. P. Davis, S. V. Rajkumar, and A. Dispenzieri
Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.
Arch Dermatol, October 1, 2006; 142(10): 1298 - 1302.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. A. Zonder, B. Barlogie, B. G. M. Durie, J. McCoy, J. Crowley, M. A. Hussein, S. V. Rajkumar, and M. A. Gertz
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.
Blood, July 1, 2006; 108(1): 403 - 404.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
S.-B. Woo, J. W. Hellstein, and J. R. Kalmar
Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws
Ann Intern Med, May 16, 2006; 144(10): 753 - 761.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Barlogie, G. Tricot, E. Rasmussen, E. Anaissie, F. van Rhee, M. Zangari, A. Fassas, K. Hollmig, M. Pineda-Roman, J. Shaughnessy, et al.
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies
Blood, April 1, 2006; 107(7): 2633 - 2638.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. Barlogie, G. Tricot, E. Anaissie, J. Shaughnessy, E. Rasmussen, F. van Rhee, A. Fassas, M. Zangari, K. Hollmig, M. Pineda-Roman, et al.
Thalidomide and Hematopoietic-Cell Transplantation for Multiple Myeloma
N. Engl. J. Med., March 9, 2006; 354(10): 1021 - 1030.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
R. L. Vessella, T. A. Guise, E. S. Susman, L. J. Suva, G. A. Clines, S. L. Kominsky, K. L. Weber, J. M. Chirgwin, L. K. McCauley, and W. Kozlow
Meeting Report from Skeletal Complications of Malignancy IV: A symposium jointly sponsored by The Paget Foundation for Paget's Disease of Bone and Related Disorders, the National Cancer Institute, and the University of Virginia School of Medicine * April 28-30, 2005 in Bethesda, Maryland, USA
IBMS BoneKEy, March 1, 2006; 3(3): 15 - 42.
[Full Text] [PDF]

Home page
 Ann OncolHome page
I. Dimopoulou, A. Bamias, P. Lyberopoulos, and M. A. Dimopoulos
Pulmonary toxicity from novel antineoplastic agents
Ann. Onc., March 1, 2006; 17(3): 372 - 379.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Barlogie, R. A. Kyle, K. C. Anderson, P. R. Greipp, H. M. Lazarus, D. D. Hurd, J. McCoy, S. R. Dakhil, K. S. Lanier, R. A. Chapman, et al.
Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321
J. Clin. Oncol., February 20, 2006; 24(6): 929 - 936.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. V. Rajkumar, E. Blood, D. Vesole, R. Fonseca, and P. R. Greipp
Phase III Clinical Trial of Thalidomide Plus Dexamethasone Compared With Dexamethasone Alone in Newly Diagnosed Multiple Myeloma: A Clinical Trial Coordinated by the Eastern Cooperative Oncology Group
J. Clin. Oncol., January 20, 2006; 24(3): 431 - 436.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Richardson and K. Anderson
Thalidomide and Dexamethasone: A New Standard of Care for Initial Therapy in Multiple Myeloma
J. Clin. Oncol., January 20, 2006; 24(3): 334 - 336.
[Full Text] [PDF]

Home page
 ASH Education BookHome page
R. Z. Orlowski
Initial Therapy of Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation
Hematology, January 1, 2006; 2006(1): 338 - 347.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. A. Zonder
Thrombotic Complications of Myeloma Therapy
Hematology, January 1, 2006; 2006(1): 348 - 355.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Moreau, C. Hullin, F. Garban, I. Yakoub-Agha, L. Benboubker, M. Attal, G. Marit, J.-G. Fuzibet, C. Doyen, L. Voillat, et al.
Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol
Blood, January 1, 2006; 107(1): 397 - 403.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-P. Fermand, S. Katsahian, M. Divine, V. Leblond, F. Dreyfus, M. Macro, B. Arnulf, B. Royer, X. Mariette, E. Pertuiset, et al.
High-Dose Therapy and Autologous Blood Stem-Cell Transplantation Compared With Conventional Treatment in Myeloma Patients Aged 55 to 65 Years: Long-Term Results of a Randomized Control Trial From the Group Myelome-Autogreffe
J. Clin. Oncol., December 20, 2005; 23(36): 9227 - 9233.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. V. Rajkumar, S. R. Hayman, M. Q. Lacy, A. Dispenzieri, S. M. Geyer, B. Kabat, S. R. Zeldenrust, S. Kumar, P. R. Greipp, R. Fonseca, et al.
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Blood, December 15, 2005; 106(13): 4050 - 4053.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. David, S.-Y. Sun, E. K. Waller, J. Chen, F. R. Khuri, and S. Lonial
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT
Blood, December 15, 2005; 106(13): 4322 - 4329.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
G. Saunders
Overview of drug therapy for multiple myeloma
Journal of Oncology Pharmacy Practice, September 1, 2005; 11(3): 83 - 100.
[Abstract] [PDF]

Home page
 BloodHome page
M. Cavo, E. Zamagni, P. Tosi, P. Tacchetti, C. Cellini, D. Cangini, A. de Vivo, N. Testoni, C. Nicci, C. Terragna, et al.
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma
Blood, July 1, 2005; 106(1): 35 - 39.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. Dispenzieri
Bortezomib for Myeloma -- Much Ado about Something
N. Engl. J. Med., June 16, 2005; 352(24): 2546 - 2548.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
M. E Gordinier and D. S Dizon
Dyspnea During Thalidomide Treatment for Advanced Ovarian Cancer
Ann. Pharmacother., May 1, 2005; 39(5): 962 - 965.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Palladini, V. Perfetti, S. Perlini, L. Obici, F. Lavatelli, R. Caccialanza, R. Invernizzi, B. Comotti, and G. Merlini
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
Blood, April 1, 2005; 105(7): 2949 - 2951.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
H. S Sano, J A. Waddell, D. A Solimando Jr, P. Doulaveris, and R. Myhand
Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost
Journal of Oncology Pharmacy Practice, March 1, 2005; 11(1): 21 - 30.
[Abstract] [PDF]

Home page
 NEJMHome page
P. G. Richardson, A. Kassarjian, and W. Jing
Case 38-2004 - A 40-Year-Old Man with a Large Tumor of the Skull
N. Engl. J. Med., December 16, 2004; 351(25): 2637 - 2645.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. K. Stewart, C. I. Chen, K. Howson-Jan, D. White, J. Roy, M. J. Kovacs, C. Shustik, A. Sadura, L. Shepherd, K. Ding, et al.
Results of a Multicenter Randomized Phase II Trial of Thalidomide and Prednisone Maintenance Therapy for Multiple Myeloma after Autologous Stem Cell Transplant
Clin. Cancer Res., December 15, 2004; 10(24): 8170 - 8176.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Hayashi, T. Hideshima, A. N. Nguyen, O. Munoz, K. Podar, M. Hamasaki, K. Ishitsuka, H. Yasui, P. Richardson, S. Chakravarty, et al.
Transforming Growth Factor {beta} Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment
Clin. Cancer Res., November 15, 2004; 10(22): 7540 - 7546.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Kroger, A. Shimoni, M. Zagrivnaja, F. Ayuk, M. Lioznov, H. Schieder, H. Renges, B. Fehse, T. Zabelina, A. Nagler, et al.
Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma
Blood, November 15, 2004; 104(10): 3361 - 3363.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. A. Kyle and S. V. Rajkumar
Multiple Myeloma
N. Engl. J. Med., October 28, 2004; 351(18): 1860 - 1873.
[Full Text] [PDF]

Home page
 Toxicol SciHome page
S. K. Teo, K. H. Denny, D. I. Stirling, S. D. Thomas, S. Morseth, and A. M. Hoberman
Effects of Thalidomide on Developmental, Peri- and Postnatal Function in Female New Zealand White Rabbits and Offspring
Toxicol. Sci., October 1, 2004; 81(2): 379 - 389.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Richardson and K. Anderson
Immunomodulatory Analogs of Thalidomide: An Emerging New Therapy in Myeloma
J. Clin. Oncol., August 15, 2004; 22(16): 3212 - 3214.
[Full Text] [PDF]

Home page
 Ann OncolHome page
V. Eleutherakis-Papaiakovou, A. Bamias, and M. A. Dimopoulos
Thalidomide in cancer medicine
Ann. Onc., August 1, 2004; 15(8): 1151 - 1160.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson
Advances in biology of multiple myeloma: clinical applications
Blood, August 1, 2004; 104(3): 607 - 618.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Kumar, T. E. Witzig, and S. V. Rajkumar
Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies
J. Clin. Oncol., June 15, 2004; 22(12): 2477 - 2488.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Sparano, R. Gray, B. Giantonio, P. O'Dwyer, and R. L. Comis
Evaluating Antiangiogenesis Agents in the Clinic: The Eastern Cooperative Oncology Group Portfolio of Clinical Trials
Clin. Cancer Res., February 15, 2004; 10(4): 1206 - 1211.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Zervas, M. A. Dimopoulos, E. Hatzicharissi, A. Anagnostopoulos, M. Papaioannou, Ch. Mitsouli, P. Panagiotidis, J. Korantzis, M. Tzilianos, and A. Maniatis
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study
Ann. Onc., January 1, 2004; 15(1): 134 - 138.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J.-L. Harousseau, J. Shaughnessy Jr., and P. Richardson
Multiple Myeloma
Hematology, January 1, 2004; 2004(1): 237 - 256.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Abdollahi, K. E. Lipson, A. Sckell, H. Zieher, F. Klenke, D. Poerschke, A. Roth, X. Han, M. Krix, M. Bischof, et al.
Combined Therapy with Direct and Indirect Angiogenesis Inhibition Results in Enhanced Antiangiogenic and Antitumor Effects
Cancer Res., December 15, 2003; 63(24): 8890 - 8898.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Dimopoulos, A. Anagnostopoulos, and D. Weber
Treatment of Plasma Cell Dyscrasias With Thalidomide and Its Derivatives
J. Clin. Oncol., December 1, 2003; 21(23): 4444 - 4454.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. K. Rowinsky
Crossing the Cancer Cell Membrane to Improve Clinical Outcomes
Oncologist, December 1, 2003; 8(90003): 1 - 4.
[Full Text] [PDF]

Home page
 The OncologistHome page
M. A. Hussein
Modifications to Therapy for Multiple Myeloma: Pegylated Liposomal Doxorubicin in Combination With Vincristine, Reduced-Dose Dexamethasone, and Thalidomide
Oncologist, December 1, 2003; 8(90003): 39 - 45.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Mileshkin, J. J. Biagi, P. Mitchell, C. Underhill, A. Grigg, R. Bell, J. McKendrick, P. Briggs, J. F. Seymour, K. Lillie, et al.
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age
Blood, July 1, 2003; 102(1): 69 - 77.
[Abstract] [Full Text] [PDF]

Home page